Number of shares and votes in Orexo Uppsala, Swede

Uppsala, Sweden – May 30, 2014 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs. Today, the last trading day of the month, there are in total 32,944,983 shares and votes in the company. For further information, please contact: Henrik Juuel, EVP and Chief Financial Officer Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com About Orexo Orexo is a specialty pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. The company is commercializing its proprietary product, Zubsolv® (buprenorphine and naloxone), in the United States for maintenance treatment of opioid dependence. Zubsolv is a novel sublingual formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the US, EU and Japan. Orexo’s development expertise is within the area of reformulation technologies, and especially sublingual formulations. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap. For information about Orexo please visit www.orexo.com Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Markets Act. The information was submitted for publication at 4:30 pm CET on May 30, 2014.